Article Text

Download PDFPDF

442-P Characterizing human Vδ1+ and Vδ2+ γδ T cells for tumor immunotherapy development
  1. Kok Fei Chan1,
  2. Tianming Li2,
  3. Simone Ostrouska2,
  4. Andrew Hammet3,
  5. Marc Rigau4,
  6. Adam P Uldrich4 and
  7. Andreas Behren2,5
  1. 1Olivia Newton-John Cancer Research Institute, Heidelberg, Australia
  2. 2Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, VIC, Australia
  3. 3CSL Limited at the Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC, Australia
  4. 4Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, Australia
  5. 5Department of Medicine, University of Melbourne, Parkville, VIC, Australia
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Immunotherapy has revolutionized the treatment of cancer, and has been instated as a ‘pillar’ of modern cancer treatments alongside chemotherapy, radiotherapy and surgery. Most tumor immunotherapy developments to date have focused on cytotoxic CD8+ T cells. Increasingly, γδ T cells are being considered as the next-generation tumor immunotherapy against difficult to treat solid tumors due to their potent cytotoxic and cytolytic functions, and natural tropism for the tumor microenvironment. Moreover, γδ T cells can recognize a broad range of tumors and infected cells without the requirement of antigen presentation via major histocompatibility complex (MHC) molecules. Previous studies have shown that a high number of γδ T cells within tumors is strongly correlated with overall patient survival across 25 cancer types.

Methods We have isolated and expanded human Vδ1+ and Vδ2+ T cells and performed in vitro T cell killing assay. In vitro isolated human Vδ2+ T cells were used for adoptive cell transfer in tumor-bearing NSG mice.

Results In our hands, we show that human Vδ1+ and Vδ2+ T cell constitute only 0.05 to 0.62% and 0.34 to 3.02%, respectively of total circulating T cells. We are now routinely isolating and expanding human Vδ1+ and Vδ2+ T cells and have immunophenotyped and validated their capability to kill different types of tumor cells in vitro. Additionally, we show that in vitro isolated human Vδ2+ T cells can slow tumor growth in vivo and prolong the survival of tumor-bearing NSG mice when adoptively transferred.

Conclusions Collectively, our data showed that human γδ T cells are promising targets for tumor immunotherapy development.

Ethics Approval ‘This study was approved by Australian Red Cross for the isolation of human Vδ2+ γδ T cells from healthy donors’ peripheral blood mononuclear cells, agreement number: 21-07VIC-09.’

‘This study was approved by Austin Health Animal Ethics Committee for adoptive cell transfer of human Vδ2+ γδ T cells into NSG mice, AEC Reference number: A2020/05661.’

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.